Previous 10 | Next 10 |
YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“ MediWound ” or the “ Company ”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announc...
MediWound Ltd. (MDWD) Q3 2022 Earnings Conference Call November 15, 2022, 8:30 am ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference Call Participants Josh Jennings - Cowen Francois Briseb...
MediWound press release ( NASDAQ: MDWD ): Q3 GAAP EPS of -$0.13 misses by $0.03 . Revenue of $5.8M (-8.9% Y/Y) beats by $1.2M . For further details see: MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $5.8M beats by $1.2M
$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market ...
MediWound ( NASDAQ: MDWD ) is scheduled to announce Q3 earnings results on Tuesday, November 15th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $4.6M (-27.8% Y/Y). Over the last 1 year, MDWD has beaten EP...
Paper published in the November 2022 issue of Podiatry Management (Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next...
YAVNE, Israel, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the th...
YAVNE, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the establishment of a Strategic Advisory Board (SAB). The ina...
YAVNE, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that positive clinical data from the Company’s EscharEx...
YAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct and ...
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...